---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-012893"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T19:52:59.965478+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell reports OpRegen Phase 1/2a data: 7.6-letter visual gain in Cohort 4 at 12 months

## Summary
- 24 patients treated; no cases of rejection or intraocular inflammation reported.
- Cohort 4 (impaired vision) averaged 7.6-letter gain in study eye at Month 12; 25% gained ≥15 letters.
- Five Cohort 4 subjects with OpRegen delivered to most/all GA area had average 12.8-letter gain and outer retinal structure improvement.
- Majority of AEs were mild (Cohort 4: 93%); most common ocular AEs related to surgical procedure (conjunctival hemorrhage, epiretinal membrane).
- OpRegen developed under worldwide collaboration with Roche and Genentech; larger controlled study needed to confirm findings.

## SEC filing metadata
- accession: 0001493152-22-012893
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000149315222012893/0001493152-22-012893-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000149315222012893/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-012893
- JSON: https://secwatch.observer/filing/0001493152-22-012893.json
- Plain text: https://secwatch.observer/filing/0001493152-22-012893.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.